Specialty Account Manager - Symbravo

Axsome Therapeutics highlights Auvelity growth, Pipeline progress at H.C. Wainwright Conference. September 19, 2026 Key points. * Auvelity remains Axsome's main growth driver: It generated more than $180 million of the company's $218.4 million in second-quarter revenue, while its new Alzheimer's disease agitation indication is supported by an expanded sales force of more than 600 representatives. * The commercial portfolio is expanding: Sunosi continues to grow, and SYMBRAVO revenue increased 30% sequentially in the second quarter as Axsome expanded its migraine sales team. * Pipeline and finances are strengthening: Axsome has several late-stage programs and upcoming clinical milestones, ended the quarter with $320 million in cash, and said it is approaching cash-flow positivity. * Five stocks to consider instead of Axsome Therapeutics. Axsome Therapeutics NASDAQ: AXSM executives highlighted growth across its commercial portfolio, an expanded sales force and multiple late-stage clinical programs during the H.C. Wainwright 28th Annual Global Investment Conference. Chief Operating Officer Mark Jacobson said the company has three marketed products: Auvelity for major depressive disorder and Alzheimer's disease agitation; Sunosi for excessive daytime sleepiness associated with obstructive sleep apnea or narcolepsy; and SYMBRAVO for the acute treatment of migraine. The company also has six product candidates in development across 10 psychiatry and neurology indications, he said. Chief Financial Officer Nick Pizzie said Axsome reported second-quarter revenue of $218.4 million, representing 46% year-over-year growth and 14% sequential growth. Auvelity generated more than $180 million of that total, while Sunosi contributed $36 million and SYMBRAVO produced $2.3 million. Auvelity growth and Alzheimer's disease agitation launch. Executives emphasized Auvelity's commercial opportunity following its recently approved indication for agitation associated with Alzheimer's disease. Jacobson said the launch began in the summer and became more fully operational in June, alongside the completion of an expansion of the company's community sales force. Pizzie said Axsome expanded its sales organization from fewer than 300 representatives to more than 600, or roughly 630 when including its long-term-care team. The company added the long-term-care-focused team after receiving the Alzheimer's disease agitation indication, according to Jacobson. "We expect to see that growth begin essentially now," Jacobson said, referring to expected effects from the field-force expansion, market-access developments and the new indication. Pizzie said the company estimates Auvelity's annual peak-sales potential at more than $8 billion, split roughly between major depressive disorder and Alzheimer's disease agitation. He said the product's annualized revenue based on second-quarter results was about $750 million, representing what he characterized as a small share of the broader antidepressant market. Discover more The company said all Medicare Part D participants have access to Auvelity for Alzheimer's disease agitation, with more than 85% of patients not requiring prior authorization and having unrestricted or first-line access, according to Pizzie. Other commercial products. Sunosi, which Axsome acquired and markets for excessive daytime sleepiness in narcolepsy and obstructive sleep apnea, continues to grow steadily, Jacobson said. Pizzie cited estimated peak-sales potential of $300 million to $500 million for the product. For SYMBRAVO, Pizzie said revenue rose 30% sequentially in the second quarter. Executives said demand and feedback have been positive, while payer access remains an important factor in the migraine market. Axsome increased the SYMBRAVO sales team from about 100 representatives to 150 representatives, with the impact of the additional personnel not yet reflected in the cited growth figures. The company estimates SYMBRAVO could have annual peak sales of $500 million to $1 billion, Pizzie said. Pipeline milestones and financial position. Axsome has an NDA under FDA review for AXS-12 in narcolepsy, with a Prescription Drug User Fee Act date of May 1, Jacobson said. The company also recently initiated a Phase 3 smoking-cessation study of AXS-05, called SUMMIT, and two Phase 3 studies of solriamfetol in children and adolescents with ADHD, called FOCUS-2 and FOCUS-3. Top-line results from the Phase 3 ENGAGE trial of solriamfetol in binge eating disorder are expected in the fourth quarter, Jacobson said. The company expects top-line results from a shift-work-disorder trial of sarampanadol next year. * Seven clinical trials are ongoing, according to Axsome. * The company is also pursuing programs in fibromyalgia, major depressive disorder with excessive sleepiness, schizophrenia, epilepsy and Tourette syndrome. * Executives said they see the potential for approximately one NDA filing annually for the foreseeable future through 2031. Pizzie said Axsome ended the second quarter with $320 million in cash, which he described as the company's strongest financial position since inception. The company reported $46 million of research and development expense and $208 million of selling, general and administrative expense during the quarter. Axsome expects selling, general and administrative spending to remain essentially level in the second half of the year, while research and development expense is expected to rise modestly as Phase 3 programs advance, Pizzie said. He added that the company is approaching cash-flow positivity and expects profitability to follow. Jacobson also highlighted the company's intellectual-property position, saying Auvelity exclusivity is expected to extend to early 2039 with pediatric exclusivity, while Sunosi's established runway extends into 2040. He said SYMBRAVO patents extend to at least 2045, with work ongoing to establish its potential exclusivity period. About Axsome Therapeutics (NASDAQ:AXSM). Axsome Therapeutics, Inc is a biopharmaceutical company focused on developing and commercializing therapies for central nervous system (CNS) disorders. The company's research programs address conditions with substantial unmet medical needs, including depression, migraine, narcolepsy, excessive daytime sleepiness, agitation associated with Alzheimer's disease, and other neurological or psychiatric disorders. Axsome's commercial portfolio includes Auvelity, an oral medicine approved in the United States for the treatment of major depressive disorder in adults. This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to [email protected]. Before you consider Axsome Therapeutics, you'll want to hear this. MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Axsome Therapeutics wasn't on the list. While Axsome Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys. Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain - combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list. Continue following MarketBeat

Axsome Therapeutics has dosed the first patient in its phase III SUMMIT study evaluating AXS-05 for smoking cessation treatment. The randomised, double-blind, placebo-controlled trial will assess the drug's safety and efficacy in adults. Active smokers will be randomly assigned to receive AXS-05, bupropion, or placebo in equal proportions for approximately 12 weeks. The primary endpoint measures smoking abstinence at the end of treatment. Axsome currently markets AXS-05 as Auvelity in the US for major depressive disorder. In April 2026, the FDA approved it for treating agitation associated with Alzheimer's-related dementia. Auvelity generated $333 million in US sales during the first half of 2026, up 54.2% year-over-year, driven by prescription growth and higher volumes.

Axsome Therapeutics' stock has risen 16% year to date, outpacing the S&P 500's 11% gain. Wall Street analysts see further upside, with an average price target of $285.42 implying 37% growth from current levels. The biotech company's revenue jumped 46% year over year to $218.4 million in the second quarter. Auvelity, its depression treatment, drove growth with $180.3 million in sales, up 51%. The company recently won FDA approval to expand Auvelity's use for Alzheimer's disease agitation, a market affecting more than five million US patients. Additional label expansions are being pursued for smoking cessation. Axsome's portfolio includes Symbravo for migraines and Sunosi for narcolepsy-related sleepiness. The company is investigating Sunosi in phase 3 studies for depression, ADHD, and binge eating disorder. Another candidate, AXS-12 for narcolepsy-related cataplexy, is currently under FDA review.